A history of radiotherapy and accompanying pulmonary embolism were selected as covariates for the multivariate analysis; although rivaroxaban presented a 1.576 (95% CI=0.752–3.305)-fold increase in risk for the composite event when compared with dalteparin, this difference did not reach statistical significance.
← all excerpts
Comparison of rivaroxaban and dalteparin for the long-term treatment of venous thromboembolism in patients with gynecologic cancers.
1
—
—